CODEX:Collection of Aflibercept Data in Routine Practice
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 30 Mar 2017
At a glance
- Drugs Aflibercept (Primary)
- Indications Branch retinal vein occlusion; Central retinal vein occlusion; Diabetic macular oedema; Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms CODEX
- Sponsors Bayer
- 23 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 06 Oct 2016 Status changed from not yet recruiting to recruiting.
- 16 Aug 2016 Planned End Date changed from 1 Dec 2018 to 1 May 2018.